New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis

CD137 (4-1BB) is a surface glycoprotein that belongs to the tumour necrosis factor receptor family (TNFRSF9). Its expression is induced on activation on a number of leucocyte types. Interestingly, for cancer immunotherapy, CD137 becomes expressed on primed T and natural killer (NK) cells, which on l...

Descripción completa

Detalles Bibliográficos
Autores principales: Etxeberria, Iñaki, Glez-Vaz, Javier, Teijeira, Álvaro, Melero, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333812/
https://www.ncbi.nlm.nih.gov/pubmed/32611557
http://dx.doi.org/10.1136/esmoopen-2020-000733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333812/
https://www.ncbi.nlm.nih.gov/pubmed/32611557
http://dx.doi.org/10.1136/esmoopen-2020-000733

Ejemplares similares